---
title: Semaphore Forms Joint Venture with Topline Strategy
description: Joint venture between Semaphore and Topline Strategy
---

[![Semaphore - Private Equity funds-under-management and technology and market due diligence](https://prev.sema4usa.com/hs-fs/file-1633455679-jpg/Sema_4usa/Semaphore_Private_Equity_funds-under-management_technology_and_market_due_diligence_logo1.jpg)](http://www.sema4usa.com/)

[![Semaphore - Private Equity funds-under-management and technology and market due diligence](https://prev.sema4usa.com/hs-fs/file-1665728779-png/images/logo.png)](http://www.sema4usa.com/)

![Boston London New York](https://prev.sema4usa.com/hs-fs/file-15279406-gif/images/banner_boston_london_new-york.gif)

## [Semaphore Forms Joint Venture with Topline Strategy](https://prev.sema4usa.com/blog/bid/69140/Semaphore-Forms-Joint-Venture-with-Topline-Strategy)

- [Tweet](https://twitter.com/share)

## Semaphore Forms Joint Venture with Topline Strategy

## to Provide Technology Due Diligence

 

As you may have read in our last S4 Reporter, Cris Miller, the founding director of our Technology Due Diligence Practice retired last Friday September 30th. With Cris’ departure, we decided to form a Joint Venture with Topline Strategy, a Boston-based provider of strategy consulting services to technology companies, in which Topline will take over day-to-day management of the practice.  It will operate under the name The Semaphore Technology Diligence Practice.

Over the last 5 years, we have formed a close partnership with Topline Strategy, working on dozens of engagements together. Together we’ve been able to provide our clients more complete answers to questions about their technologies and the markets for those technologies. 

With the retirement of Cris Miller, who was the driving force behind our Technology Due Diligence practice, we thought the best way to continue our commitment to clients as well as grow the practice was through a Joint Venture with Topline Strategy. Through our long partnership, the Topline team has demonstrated a true understanding of Technology Due Diligence as well as built strong relationships with our principal technologists and major clients. Having them take the business forward was a natural.  We have been working together on the creation of, and transition to this, Joint Venture for the last three months.

As part of the agreement Cris Miller will be joining Topline Strategy as an advisor and Topline Strategy will continue to work closely with our Private Equity Advisory group, providing both strategy consulting and technology due diligence services to Semaphore’s clients and portfolio companies.

As Topline Strategy will be the operating partner in our Joint Venture, going forward, please feel free to contact Jon Klein ([jon@toplinestrategy.com](mailto:jon@toplinestrategy.com)) with any questions about Technology Diligence or visit its website www.toplinestrategy.com. Of course, you can also reach me ([mdisalvo@sema4usa.com](mailto:mdisalvo@sema4usa.com)) if you have any questions.  I know you join us in wishing Cris well in his retirement as Topline and Semaphore  continue to fulfill our common promise and commitment to aiding investors and the M&A community with the right knowledge and correct solutions to ensure success.

*Mark S. DiSalvo is the President and CEO of Sema4 Inc., dba Semaphore ([www.sema4usa.com](http://www.sema4usa.com/)), a leading global professional services provider of Private Equity funds-under-management. Semaphore currently holds fiduciary obligations as General Partner for seven Private Equity and Venture Capital funds, is a New Markets Tax Credit lender and advises General and Limited Partners as well as corporations around the world. Semaphore’s corporate offices are in Boston with principal offices in New York and London.*

 Topics: [Technology Assessment](https://prev.sema4usa.com/blog/topic/technology-assessment), [due diligence](https://prev.sema4usa.com/blog/topic/due-diligence), [private equity funds](https://prev.sema4usa.com/blog/topic/private-equity-funds), [Semaphore](https://prev.sema4usa.com/blog/topic/semaphore), [technology diligence](https://prev.sema4usa.com/blog/topic/technology-diligence), [business advisory](https://prev.sema4usa.com/blog/topic/business-advisory), [technology](https://prev.sema4usa.com/blog/topic/technology), [diligence](https://prev.sema4usa.com/blog/topic/diligence)

### Subscribe by Email

### Most Popular Posts

### Browse by Tag

- [American entrepreneurism (1)](https://prev.sema4usa.com/blog/topic/american-entrepreneurism)
- [analysis (2)](https://prev.sema4usa.com/blog/topic/analysis)
- [Announcements (1)](https://prev.sema4usa.com/blog/topic/announcements)
- [Biotech (2)](https://prev.sema4usa.com/blog/topic/biotech)
- [BOSS (1)](https://prev.sema4usa.com/blog/topic/boss)
- [business (5)](https://prev.sema4usa.com/blog/topic/business)
- [business advisory (4)](https://prev.sema4usa.com/blog/topic/business-advisory)
- [Business Operations (2)](https://prev.sema4usa.com/blog/topic/business-operations)
- [Corporate Growth Planning (2)](https://prev.sema4usa.com/blog/topic/corporate-growth-planning)
- [diligence (13)](https://prev.sema4usa.com/blog/topic/diligence)
- [due diligence (12)](https://prev.sema4usa.com/blog/topic/due-diligence)
- [entrepreneurs (3)](https://prev.sema4usa.com/blog/topic/entrepreneurs)
- [equity (10)](https://prev.sema4usa.com/blog/topic/equity)
- [ethical standards (2)](https://prev.sema4usa.com/blog/topic/ethical-standards)
- [ethics (3)](https://prev.sema4usa.com/blog/topic/ethics)
- [finance advice (2)](https://prev.sema4usa.com/blog/topic/finance-advice)
- [funds under management (6)](https://prev.sema4usa.com/blog/topic/funds-under-management)
- [general partners (14)](https://prev.sema4usa.com/blog/topic/general-partners)
- [growth equity investments (3)](https://prev.sema4usa.com/blog/topic/growth-equity-investments)
- [ILPA (1)](https://prev.sema4usa.com/blog/topic/ilpa)
- [ILPA Principles (1)](https://prev.sema4usa.com/blog/topic/ilpa-principles)
- [investment (11)](https://prev.sema4usa.com/blog/topic/investment)
- [Life Sciences (2)](https://prev.sema4usa.com/blog/topic/life-sciences)
- [limited partners (14)](https://prev.sema4usa.com/blog/topic/limited-partners)
- [LP (5)](https://prev.sema4usa.com/blog/topic/lp)
- [market (3)](https://prev.sema4usa.com/blog/topic/market)
- [market diligence (11)](https://prev.sema4usa.com/blog/topic/market-diligence)
- [market diligence; law firms; (2)](https://prev.sema4usa.com/blog/topic/market-diligence-law-firms)
- [new markets tax credits (2)](https://prev.sema4usa.com/blog/topic/new-markets-tax-credits)
- [Olympics (1)](https://prev.sema4usa.com/blog/topic/olympics)
- [operations (3)](https://prev.sema4usa.com/blog/topic/operations)
- [Pipeline Interviews (3)](https://prev.sema4usa.com/blog/topic/pipeline-interviews)
- [portfolio company (2)](https://prev.sema4usa.com/blog/topic/portfolio-company)
- [private equity (6)](https://prev.sema4usa.com/blog/topic/private-equity)
- [private equity funds (16)](https://prev.sema4usa.com/blog/topic/private-equity-funds)
- [SBIR (1)](https://prev.sema4usa.com/blog/topic/sbir)
- [Semaphore (22)](https://prev.sema4usa.com/blog/topic/semaphore)
- [small businesses (2)](https://prev.sema4usa.com/blog/topic/small-businesses)
- [Strategy Services (1)](https://prev.sema4usa.com/blog/topic/strategy-services)
- [Survey (10)](https://prev.sema4usa.com/blog/topic/survey)
- [technology (12)](https://prev.sema4usa.com/blog/topic/technology)
- [Technology Assessment (3)](https://prev.sema4usa.com/blog/topic/technology-assessment)
- [technology diligence (7)](https://prev.sema4usa.com/blog/topic/technology-diligence)
- [troubled funds (12)](https://prev.sema4usa.com/blog/topic/troubled-funds)
- [turnaround (4)](https://prev.sema4usa.com/blog/topic/turnaround)
- [valley of death (1)](https://prev.sema4usa.com/blog/topic/valley-of-death)
- [VC (7)](https://prev.sema4usa.com/blog/topic/vc)
- [Venture Capital (17)](https://prev.sema4usa.com/blog/topic/venture-capital)
- [venture funds (9)](https://prev.sema4usa.com/blog/topic/venture-funds)

### Posts by Month

- [June 2010 (3)](https://prev.sema4usa.com/blog/archive/2010/06)
- [April 2011 (3)](https://prev.sema4usa.com/blog/archive/2011/04)
- [November 2009 (2)](https://prev.sema4usa.com/blog/archive/2009/11)
- [December 2009 (2)](https://prev.sema4usa.com/blog/archive/2009/12)
- [January 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/01)
- [February 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/02)
- [July 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/07)
- [September 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/09)
- [October 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/10)
- [December 2013 (2)](https://prev.sema4usa.com/blog/archive/2013/12)
- [March 2010 (1)](https://prev.sema4usa.com/blog/archive/2010/03)
- [January 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/01)
- [March 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/03)
- [September 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/09)
- [October 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/10)
- [December 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/12)
- [February 2012 (1)](https://prev.sema4usa.com/blog/archive/2012/02)
- [July 2012 (1)](https://prev.sema4usa.com/blog/archive/2012/07)
- [November 2012 (1)](https://prev.sema4usa.com/blog/archive/2012/11)
- [January 2013 (1)](https://prev.sema4usa.com/blog/archive/2013/01)
- [April 2013 (1)](https://prev.sema4usa.com/blog/archive/2013/04)
- [May 2013 (1)](https://prev.sema4usa.com/blog/archive/2013/05)
- [July 2013 (1)](https://prev.sema4usa.com/blog/archive/2013/07)
- [February 2014 (1)](https://prev.sema4usa.com/blog/archive/2014/02)
- [August 2014 (1)](https://prev.sema4usa.com/blog/archive/2014/08)
- [December 2014 (1)](https://prev.sema4usa.com/blog/archive/2014/12)
- [February 2015 (1)](https://prev.sema4usa.com/blog/archive/2015/02)
- [August 2015 (1)](https://prev.sema4usa.com/blog/archive/2015/08)
- [January 2016 (1)](https://prev.sema4usa.com/blog/archive/2016/01)
- [February 2016 (1)](https://prev.sema4usa.com/blog/archive/2016/02)
- [August 2016 (1)](https://prev.sema4usa.com/blog/archive/2016/08)
- [January 2017 (1)](https://prev.sema4usa.com/blog/archive/2017/01)
- [February 2017 (1)](https://prev.sema4usa.com/blog/archive/2017/02)
- [August 2017 (1)](https://prev.sema4usa.com/blog/archive/2017/08)
- [January 2018 (1)](https://prev.sema4usa.com/blog/archive/2018/01)
- [February 2018 (1)](https://prev.sema4usa.com/blog/archive/2018/02)
- [February 2019 (1)](https://prev.sema4usa.com/blog/archive/2019/02)
- [February 2020 (1)](https://prev.sema4usa.com/blog/archive/2020/02)
- [February 2021 (1)](https://prev.sema4usa.com/blog/archive/2021/02)
- [January 2022 (1)](https://prev.sema4usa.com/blog/archive/2022/01)
- [February 2022 (1)](https://prev.sema4usa.com/blog/archive/2022/02)
- [February 2023 (1)](https://prev.sema4usa.com/blog/archive/2023/02)
- [February 2024 (1)](https://prev.sema4usa.com/blog/archive/2024/02)
- [February 2025 (1)](https://prev.sema4usa.com/blog/archive/2025/02)

- [Home ](http://www.sema4usa.com/)|
- [Services ](http://www.sema4usa.com/Technology-Diligence-and-Funds-Under-Management-Services/)|
- [About Us ](http://www.sema4usa.com/About-our-Funds-Under-Management-and-Technology-and-Market-Due-Diligence/)|
- [Semaphore Client List ](http://www.sema4usa.com/semaphore-client-list/)|
- [Blog ](http://www.sema4usa.com/blog/)|
- [Contact Semaphore ](http://www.sema4usa.com/contact-semaphore/)|
- [Semaphore Connections ](http://www.sema4usa.com/semaphore-connections/)

© 2020 Semaphore. All rights reserved.